VELOSBIO

VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers. It was founded in 2017 and headquartered in San Diego, California.